(Q50931012)

English

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.

scientific article published in July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. (English)

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

author name string

Cengiz Akkaya

1

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

Enver Yusuf Sivrioglu

2

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

Semra Akgoz

3

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

Salih Saygin Eker

4

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

Selcuk Kirli

5

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

publication date

1 July 2006

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

Human Psychopharmacology

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

21

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

337-345

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

5

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

Time-related predictors of suicide in major affective disorder.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

21 January 2018

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

21 January 2018

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

21 January 2018

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

21 January 2018

The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

21 January 2018

Citalopram Therapy for Depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

21 January 2018

Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Anxious and nonanxious depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Mixed anxiety-depression in a primary-care clinic

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Venlafaxine extended-release: a review of its use in the management of major depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.770

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HUP.770

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/16856215

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50931012&oldid=1465469045"